Hatim Sabaawy
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Organoids | 3 | 2021 | 104 | 2.030 |
Why?
| Neoplastic Stem Cells | 3 | 2016 | 378 | 1.050 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2017 | 48 | 1.040 |
Why?
| Antineoplastic Agents | 6 | 2021 | 2044 | 1.000 |
Why?
| Prostatic Neoplasms | 3 | 2021 | 995 | 0.990 |
Why?
| Glioblastoma | 2 | 2021 | 322 | 0.920 |
Why?
| Bone Marrow Cells | 3 | 2014 | 302 | 0.880 |
Why?
| Spinal Cord Injuries | 4 | 2014 | 195 | 0.820 |
Why?
| Zebrafish | 9 | 2022 | 460 | 0.800 |
Why?
| Bone Marrow Transplantation | 2 | 2014 | 277 | 0.780 |
Why?
| Cell Culture Techniques | 2 | 2021 | 347 | 0.770 |
Why?
| STAT Transcription Factors | 1 | 2021 | 14 | 0.760 |
Why?
| Janus Kinases | 1 | 2021 | 12 | 0.760 |
Why?
| Apoptosis Regulatory Proteins | 2 | 2012 | 182 | 0.740 |
Why?
| Biological Assay | 1 | 2021 | 119 | 0.720 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2021 | 804 | 0.710 |
Why?
| Hepatocytes | 1 | 2021 | 215 | 0.680 |
Why?
| Hematopoietic Stem Cells | 3 | 2012 | 382 | 0.680 |
Why?
| Precision Medicine | 2 | 2021 | 385 | 0.650 |
Why?
| Carcinoma, Hepatocellular | 2 | 2017 | 270 | 0.550 |
Why?
| Cell Survival | 4 | 2016 | 1084 | 0.540 |
Why?
| Small Molecule Libraries | 1 | 2017 | 86 | 0.520 |
Why?
| Zebrafish Proteins | 4 | 2022 | 268 | 0.500 |
Why?
| Cell Self Renewal | 1 | 2016 | 53 | 0.500 |
Why?
| Erythroid Cells | 2 | 2012 | 9 | 0.500 |
Why?
| Cell Differentiation | 3 | 2012 | 1895 | 0.500 |
Why?
| Radiation-Sensitizing Agents | 1 | 2015 | 39 | 0.470 |
Why?
| Liver Neoplasms | 2 | 2017 | 635 | 0.450 |
Why?
| Adenocarcinoma | 3 | 2013 | 889 | 0.450 |
Why?
| Quinoxalines | 1 | 2015 | 64 | 0.450 |
Why?
| Nanotechnology | 1 | 2015 | 121 | 0.440 |
Why?
| Brain Neoplasms | 2 | 2021 | 1149 | 0.440 |
Why?
| Nerve Regeneration | 1 | 2014 | 62 | 0.440 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 427 | 0.440 |
Why?
| Benzimidazoles | 1 | 2015 | 162 | 0.430 |
Why?
| Hematologic Neoplasms | 1 | 2015 | 141 | 0.420 |
Why?
| Liver | 1 | 2021 | 1836 | 0.410 |
Why?
| Megakaryocytes | 1 | 2012 | 32 | 0.400 |
Why?
| Embryonic Development | 2 | 2013 | 113 | 0.390 |
Why?
| Cell Adhesion | 1 | 2013 | 454 | 0.380 |
Why?
| Cell Line, Tumor | 6 | 2022 | 3181 | 0.370 |
Why?
| Core Binding Factor Alpha 2 Subunit | 2 | 2012 | 32 | 0.360 |
Why?
| Inflammation | 1 | 2021 | 2741 | 0.350 |
Why?
| Signal Transduction | 2 | 2021 | 4916 | 0.330 |
Why?
| Hep G2 Cells | 2 | 2021 | 61 | 0.330 |
Why?
| Immunohistochemistry | 3 | 2021 | 1684 | 0.320 |
Why?
| Brain | 2 | 2021 | 2675 | 0.310 |
Why?
| Animals | 20 | 2023 | 35334 | 0.310 |
Why?
| Exercise Therapy | 1 | 2013 | 414 | 0.300 |
Why?
| Fluorouracil | 2 | 1999 | 197 | 0.290 |
Why?
| Interferon-alpha | 2 | 1999 | 194 | 0.280 |
Why?
| Gene Knockdown Techniques | 3 | 2013 | 315 | 0.280 |
Why?
| Receptors, Androgen | 2 | 2020 | 143 | 0.280 |
Why?
| Lymphoma, AIDS-Related | 1 | 2007 | 14 | 0.270 |
Why?
| Neoplasms | 1 | 2021 | 2450 | 0.270 |
Why?
| Cell Transformation, Neoplastic | 2 | 2021 | 318 | 0.270 |
Why?
| Mice, Inbred NOD | 2 | 2021 | 587 | 0.270 |
Why?
| Drug Resistance, Neoplasm | 2 | 2021 | 751 | 0.260 |
Why?
| Lymphoproliferative Disorders | 1 | 2007 | 54 | 0.260 |
Why?
| Colonic Neoplasms | 2 | 1999 | 241 | 0.260 |
Why?
| Cell Proliferation | 4 | 2021 | 2367 | 0.260 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2007 | 79 | 0.260 |
Why?
| Apoptosis | 6 | 2020 | 2488 | 0.250 |
Why?
| Disease Models, Animal | 4 | 2014 | 4073 | 0.250 |
Why?
| Molecular Targeted Therapy | 2 | 2021 | 391 | 0.250 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 76 | 0.240 |
Why?
| Humans | 27 | 2023 | 129527 | 0.240 |
Why?
| F-Box Proteins | 2 | 2016 | 24 | 0.230 |
Why?
| Heme Oxygenase (Decyclizing) | 2 | 2001 | 22 | 0.230 |
Why?
| Oncogene Proteins, Fusion | 1 | 2006 | 200 | 0.230 |
Why?
| Transplantation, Autologous | 3 | 2014 | 213 | 0.220 |
Why?
| Mice | 8 | 2023 | 16973 | 0.210 |
Why?
| Morpholinos | 2 | 2013 | 30 | 0.200 |
Why?
| Ear, Inner | 1 | 2022 | 45 | 0.200 |
Why?
| Genetic Therapy | 2 | 2001 | 286 | 0.190 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2021 | 14 | 0.190 |
Why?
| Antimetabolites, Antineoplastic | 2 | 1999 | 91 | 0.190 |
Why?
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2021 | 15 | 0.190 |
Why?
| Glucose-6-Phosphatase | 1 | 2021 | 31 | 0.190 |
Why?
| Cell Shape | 1 | 2021 | 56 | 0.190 |
Why?
| Freezing | 1 | 2021 | 87 | 0.180 |
Why?
| Combined Modality Therapy | 2 | 2021 | 1201 | 0.180 |
Why?
| SOX9 Transcription Factor | 2 | 2023 | 24 | 0.180 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 58 | 0.180 |
Why?
| Culture Media | 1 | 2021 | 162 | 0.180 |
Why?
| Albumins | 1 | 2021 | 104 | 0.180 |
Why?
| Gene Transfer Techniques | 2 | 1999 | 163 | 0.180 |
Why?
| Tumor Microenvironment | 2 | 2023 | 627 | 0.180 |
Why?
| Drug Evaluation, Preclinical | 1 | 2021 | 171 | 0.180 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2021 | 191 | 0.180 |
Why?
| Fluorescent Antibody Technique | 1 | 2021 | 376 | 0.170 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 54 | 0.170 |
Why?
| Prodrugs | 1 | 2021 | 48 | 0.170 |
Why?
| Heterografts | 1 | 2021 | 134 | 0.170 |
Why?
| Tumor Cells, Cultured | 3 | 2015 | 931 | 0.170 |
Why?
| Biomarkers | 2 | 2021 | 3968 | 0.170 |
Why?
| Histological Techniques | 1 | 2020 | 40 | 0.170 |
Why?
| Androgen Antagonists | 1 | 2020 | 79 | 0.170 |
Why?
| Lung Neoplasms | 2 | 2023 | 2342 | 0.160 |
Why?
| Gene Expression | 3 | 2012 | 1461 | 0.160 |
Why?
| Disease Susceptibility | 1 | 2021 | 333 | 0.160 |
Why?
| Printing, Three-Dimensional | 1 | 2020 | 88 | 0.160 |
Why?
| Protein Isoforms | 1 | 2020 | 392 | 0.160 |
Why?
| Mitosis | 2 | 2012 | 180 | 0.160 |
Why?
| Recovery of Function | 2 | 2014 | 644 | 0.150 |
Why?
| Inflammation Mediators | 1 | 2021 | 503 | 0.150 |
Why?
| Gene Expression Regulation | 2 | 2021 | 2544 | 0.140 |
Why?
| Disease Management | 1 | 2021 | 591 | 0.140 |
Why?
| Male | 10 | 2021 | 63586 | 0.140 |
Why?
| Gene Expression Regulation, Developmental | 3 | 2013 | 819 | 0.140 |
Why?
| Carcinoma, Squamous Cell | 1 | 2022 | 628 | 0.140 |
Why?
| Transduction, Genetic | 2 | 2012 | 124 | 0.130 |
Why?
| Biomarkers, Tumor | 2 | 2021 | 1159 | 0.130 |
Why?
| Nanoparticles | 1 | 2021 | 376 | 0.130 |
Why?
| Genetic Vectors | 2 | 2012 | 309 | 0.130 |
Why?
| Genomics | 1 | 2021 | 715 | 0.130 |
Why?
| Disease Progression | 2 | 2021 | 2628 | 0.120 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2016 | 149 | 0.120 |
Why?
| Retroviridae | 3 | 2001 | 96 | 0.120 |
Why?
| Mice, SCID | 1 | 2016 | 350 | 0.120 |
Why?
| Neurons | 3 | 2022 | 1509 | 0.120 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2016 | 157 | 0.120 |
Why?
| HEK293 Cells | 1 | 2017 | 695 | 0.110 |
Why?
| Spinal Cord | 2 | 2014 | 352 | 0.110 |
Why?
| Contusions | 1 | 2014 | 20 | 0.110 |
Why?
| Blood Pressure | 1 | 2001 | 1735 | 0.110 |
Why?
| Injections, Spinal | 1 | 2014 | 105 | 0.110 |
Why?
| DNA Damage | 1 | 2016 | 383 | 0.110 |
Why?
| Racemases and Epimerases | 1 | 2013 | 11 | 0.110 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1050 | 0.110 |
Why?
| Transcriptional Regulator ERG | 1 | 2013 | 17 | 0.110 |
Why?
| CHARGE Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
| Dogs | 1 | 2014 | 385 | 0.100 |
Why?
| Collagen Type I | 1 | 2013 | 118 | 0.100 |
Why?
| Evoked Potentials, Somatosensory | 1 | 2013 | 33 | 0.100 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2013 | 60 | 0.100 |
Why?
| Prostate-Specific Antigen | 1 | 2013 | 159 | 0.100 |
Why?
| Microscopy, Fluorescence | 1 | 2014 | 397 | 0.100 |
Why?
| Cell Cycle Proteins | 1 | 2016 | 583 | 0.100 |
Why?
| Adult | 4 | 2021 | 35505 | 0.100 |
Why?
| K562 Cells | 1 | 2012 | 85 | 0.100 |
Why?
| Lentivirus | 1 | 2012 | 53 | 0.100 |
Why?
| Cytarabine | 1 | 2012 | 57 | 0.100 |
Why?
| Antigens, CD34 | 1 | 2012 | 88 | 0.100 |
Why?
| Erythropoiesis | 1 | 2012 | 51 | 0.100 |
Why?
| HIV Infections | 1 | 2007 | 2729 | 0.100 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2013 | 77 | 0.100 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2012 | 50 | 0.100 |
Why?
| Hypertension | 1 | 2001 | 1235 | 0.100 |
Why?
| Single-Blind Method | 1 | 2013 | 269 | 0.100 |
Why?
| Motor Activity | 2 | 2014 | 686 | 0.100 |
Why?
| DNA Helicases | 1 | 2013 | 146 | 0.090 |
Why?
| Embryo, Nonmammalian | 1 | 2012 | 166 | 0.090 |
Why?
| Mice, Nude | 1 | 2013 | 677 | 0.090 |
Why?
| Organ Specificity | 1 | 2012 | 296 | 0.090 |
Why?
| Tachykinins | 1 | 2011 | 6 | 0.090 |
Why?
| Antigens, CD | 1 | 2014 | 485 | 0.090 |
Why?
| Spinal Cord Regeneration | 1 | 2011 | 2 | 0.090 |
Why?
| Hematopoiesis | 1 | 2012 | 184 | 0.090 |
Why?
| Neovascularization, Physiologic | 1 | 2012 | 173 | 0.090 |
Why?
| Cancer Vaccines | 1 | 2012 | 164 | 0.090 |
Why?
| Trans-Activators | 1 | 2013 | 392 | 0.090 |
Why?
| RNA Interference | 1 | 2012 | 450 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 1 | 2015 | 2013 | 0.090 |
Why?
| Transcription Factors | 2 | 2022 | 1642 | 0.080 |
Why?
| Leukemia | 1 | 2012 | 230 | 0.080 |
Why?
| Molecular Sequence Data | 3 | 2013 | 2827 | 0.080 |
Why?
| Animals, Genetically Modified | 2 | 2007 | 231 | 0.080 |
Why?
| Dendritic Cells | 1 | 2012 | 481 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2021 | 2101 | 0.080 |
Why?
| Transfection | 2 | 2020 | 916 | 0.080 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2012 | 502 | 0.070 |
Why?
| Repressor Proteins | 1 | 2011 | 404 | 0.070 |
Why?
| Base Sequence | 2 | 2013 | 2138 | 0.070 |
Why?
| Immunotherapy | 1 | 2012 | 596 | 0.070 |
Why?
| Middle Aged | 4 | 2015 | 31087 | 0.070 |
Why?
| RNA-Binding Protein EWS | 1 | 2007 | 24 | 0.070 |
Why?
| Nerve Tissue Proteins | 1 | 2011 | 569 | 0.070 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2007 | 151 | 0.070 |
Why?
| Chronic Disease | 1 | 2013 | 1722 | 0.070 |
Why?
| RNA, Messenger | 3 | 2013 | 2697 | 0.070 |
Why?
| bcl-2-Associated X Protein | 1 | 2006 | 55 | 0.070 |
Why?
| DNA-Binding Proteins | 1 | 2013 | 1438 | 0.060 |
Why?
| Gene Silencing | 1 | 2006 | 189 | 0.060 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1684 | 0.060 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 232 | 0.060 |
Why?
| Heme Oxygenase-1 | 2 | 2001 | 62 | 0.060 |
Why?
| DNA, Neoplasm | 1 | 2005 | 153 | 0.060 |
Why?
| MicroRNAs | 1 | 2011 | 677 | 0.060 |
Why?
| Female | 6 | 2021 | 68650 | 0.060 |
Why?
| Rats | 3 | 2021 | 5470 | 0.060 |
Why?
| RNA-Binding Proteins | 1 | 2007 | 388 | 0.050 |
Why?
| Up-Regulation | 1 | 2006 | 832 | 0.050 |
Why?
| Biopsy | 1 | 2007 | 1087 | 0.050 |
Why?
| Genes, ras | 1 | 2023 | 95 | 0.050 |
Why?
| Central Nervous System Neoplasms | 1 | 2005 | 149 | 0.050 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 80 | 0.050 |
Why?
| Carboplatin | 1 | 2022 | 139 | 0.050 |
Why?
| Protein Binding | 3 | 2016 | 2121 | 0.050 |
Why?
| Polymerase Chain Reaction | 1 | 2005 | 1031 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 259 | 0.050 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 118 | 0.050 |
Why?
| Pyrazines | 1 | 2022 | 87 | 0.050 |
Why?
| Treatment Outcome | 2 | 2013 | 10232 | 0.050 |
Why?
| Rats, Inbred SHR | 1 | 2001 | 44 | 0.050 |
Why?
| Culture Techniques | 1 | 2001 | 81 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 279 | 0.050 |
Why?
| Chimera | 1 | 2001 | 57 | 0.050 |
Why?
| Arterioles | 1 | 2001 | 50 | 0.050 |
Why?
| Paclitaxel | 1 | 2022 | 217 | 0.050 |
Why?
| Neurogenesis | 1 | 2022 | 126 | 0.050 |
Why?
| Magnetic Resonance Imaging | 1 | 2013 | 3392 | 0.040 |
Why?
| Triazoles | 1 | 2022 | 148 | 0.040 |
Why?
| Models, Biological | 3 | 2016 | 1717 | 0.040 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 353 | 0.040 |
Why?
| Pressure | 1 | 2001 | 239 | 0.040 |
Why?
| Vasoconstriction | 1 | 2001 | 199 | 0.040 |
Why?
| Spheroids, Cellular | 1 | 2020 | 76 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2022 | 393 | 0.040 |
Why?
| Blotting, Northern | 1 | 1999 | 196 | 0.040 |
Why?
| 3T3 Cells | 1 | 1999 | 159 | 0.040 |
Why?
| Neural Stem Cells | 1 | 2020 | 142 | 0.040 |
Why?
| Aged | 2 | 2015 | 22063 | 0.040 |
Why?
| DNA, Complementary | 1 | 1999 | 266 | 0.040 |
Why?
| Drug Synergism | 1 | 1999 | 370 | 0.040 |
Why?
| Weight Gain | 1 | 2001 | 510 | 0.040 |
Why?
| Cell Division | 1 | 1999 | 787 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 952 | 0.030 |
Why?
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 6 | 0.030 |
Why?
| Young Adult | 1 | 2013 | 12438 | 0.030 |
Why?
| Oligonucleotides, Antisense | 2 | 2011 | 111 | 0.030 |
Why?
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 70 | 0.030 |
Why?
| Ubiquitination | 1 | 2016 | 98 | 0.030 |
Why?
| Proteolysis | 1 | 2016 | 167 | 0.030 |
Why?
| Protein Interaction Domains and Motifs | 1 | 2016 | 139 | 0.030 |
Why?
| DNA | 1 | 2022 | 1400 | 0.030 |
Why?
| Membrane Proteins | 1 | 2001 | 1118 | 0.030 |
Why?
| Cell Death | 1 | 2016 | 352 | 0.030 |
Why?
| Adolescent | 1 | 2013 | 20409 | 0.030 |
Why?
| Ultraviolet Rays | 1 | 2016 | 383 | 0.030 |
Why?
| Kidney | 1 | 2001 | 1382 | 0.030 |
Why?
| Gene Targeting | 1 | 2013 | 81 | 0.030 |
Why?
| RNA, Ribosomal | 1 | 2013 | 161 | 0.020 |
Why?
| Hepatic Encephalopathy | 1 | 2012 | 20 | 0.020 |
Why?
| Neural Crest | 1 | 2013 | 115 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2012 | 148 | 0.020 |
Why?
| Liver Function Tests | 1 | 2012 | 112 | 0.020 |
Why?
| Phosphorylation | 1 | 2016 | 1714 | 0.020 |
Why?
| Cartilage | 1 | 2013 | 183 | 0.020 |
Why?
| Activating Transcription Factors | 1 | 2011 | 2 | 0.020 |
Why?
| Co-Repressor Proteins | 1 | 2011 | 18 | 0.020 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 52 | 0.020 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2011 | 84 | 0.020 |
Why?
| Transcription Factor AP-1 | 1 | 2011 | 88 | 0.020 |
Why?
| Response Elements | 1 | 2011 | 89 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2011 | 190 | 0.020 |
Why?
| rhoA GTP-Binding Protein | 1 | 2011 | 84 | 0.020 |
Why?
| Genes, Reporter | 1 | 2011 | 265 | 0.020 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 141 | 0.020 |
Why?
| Tretinoin | 1 | 2011 | 121 | 0.020 |
Why?
| Cell Cycle | 1 | 2013 | 583 | 0.020 |
Why?
| Child | 2 | 2006 | 20932 | 0.020 |
Why?
| Lung | 1 | 2022 | 3928 | 0.020 |
Why?
| Interferon-gamma | 1 | 2012 | 773 | 0.020 |
Why?
| Flow Cytometry | 1 | 2012 | 1158 | 0.020 |
Why?
| Binding Sites | 1 | 2011 | 1250 | 0.020 |
Why?
| Sequence Homology, Amino Acid | 1 | 2007 | 371 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 855 | 0.020 |
Why?
| Palliative Care | 1 | 2012 | 704 | 0.020 |
Why?
| Preservation, Biological | 1 | 2005 | 7 | 0.010 |
Why?
| Phenotype | 1 | 2013 | 3058 | 0.010 |
Why?
| Cells, Cultured | 1 | 2011 | 4087 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2007 | 2055 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2012 | 4891 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2503 | 0.010 |
Why?
| Time Factors | 1 | 2012 | 6530 | 0.010 |
Why?
| Tin Compounds | 1 | 2001 | 17 | 0.010 |
Why?
| Heme | 1 | 2001 | 77 | 0.010 |
Why?
| Tissue Distribution | 1 | 2001 | 315 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2001 | 1091 | 0.010 |
Why?
| Prognosis | 1 | 2005 | 3772 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2001 | 2393 | 0.010 |
Why?
|
|
Sabaawy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|